ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3

BioSpaceView source article

Part of story

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics reported an 82% tumor response rate in a clinical trial combining targeted drugs for advanced pancreatic cancer, presented at ESMO congress.

Oct 23, 20262 sourcesCancer treatment Cancer research Cancer & Oncology Oncology Cancer treatment breakthroughs Clinical trials Targeted cancer therapy Drug development

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Other sources for this story

STAT News